Journal ArticleDOI
ERBB receptors and cancer: the complexity of targeted inhibitors.
Nancy E. Hynes,Heidi Lane +1 more
TLDR
This work discusses the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response, and many ERBB inhibitors used in the clinic.Abstract:
ERBB receptor tyrosine kinases have important roles in human cancer. In particular, the expression or activation of epidermal growth factor receptor and ERBB2 are altered in many epithelial tumours, and clinical studies indicate that they have important roles in tumour aetiology and progression. Accordingly, these receptors have been intensely studied to understand their importance in cancer biology and as therapeutic targets, and many ERBB inhibitors are now used in the clinic. We will discuss the significance of these receptors as clinical targets, in particular the molecular mechanisms underlying response.read more
Citations
More filters
Journal ArticleDOI
Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation
Jung Mao Hsu,Chun Te Chen,Chun Te Chen,Chao Kai Chou,Chao Kai Chou,Hsu Ping Kuo,Hsu Ping Kuo,Long Yuan Li,Chun Yi Lin,Hong Jen Lee,Hong Jen Lee,Ying Nai Wang,Mo Liu,Mo Liu,Hsin Wei Liao,Hsin Wei Liao,Bin Shi,Chien-Chen Lai,Mark T. Bedford,Chang Hai Tsai,Chang Hai Tsai,Mien Chie Hung +21 more
TL;DR: A model in which the regulatory crosstalk between PRMT5-mediated Arg 1175 methylation and EGF-induced Tyr 1173 phosphorylation attenuates EGFR-mediated ERK activation is proposed.
Journal ArticleDOI
GEP100 links epidermal growth factor receptor signalling to Arf6 activation to induce breast cancer invasion.
Masaki Morishige,Shigeru Hashimoto,Eiji Ogawa,Yoshinobu Toda,Hirokazu Kotani,Mayumi Hirose,Shumei Wei,Ari Hashimoto,Atsuko Yamada,Hajime Yano,Yuichi Mazaki,Hiroshi Kodama,Yoshinori Nio,Toshiaki Manabe,Hiromi Wada,Hidenori Kobayashi,Hisataka Sabe,Hisataka Sabe +17 more
TL;DR: The results indicate that GEP100 links EGFR signalling to Arf6 activation to induce invasive activities of some breast cancer cells, and hence may contribute to their metastasis and malignancy.
Journal ArticleDOI
Elevation of Receptor Tyrosine Kinase EphA2 Mediates Resistance to Trastuzumab Therapy
Guanglei Zhuang,Dana M. Brantley-Sieders,David B. Vaught,Jian Yu,Lu Xie,Sam Wells,Dowdy Jackson,Rebecca S. Muraoka-Cook,Carlos L. Arteaga,Jin Chen +9 more
TL;DR: It is found that EphA2 overexpression correlated with a decrease in disease-free and overall survival of HER2-overexpressing patients, and mechanistic insights into the basis for trastuzumab resistance are offered.
Journal ArticleDOI
Structure, evolution, and biology of the MUC4 mucin
TL;DR: The heavily glycosylated tandem repeat domain provides the structural rigidity to the extended extracellular region of MUC4, which serves as a barrier for some cell‐cell and cell‐extracellular matrix interactions and as a potential reservoir for certain growth factors.
Journal ArticleDOI
Endocytic downregulation of ErbB receptors: mechanisms and relevance in cancer
TL;DR: It is outlined how ErbB receptors can escape endocytic downregulation in cancer, and how targeted anti-cancer therapy may induce endocytical downregulation of Erb B receptors is discussed.
References
More filters
Journal ArticleDOI
The hallmarks of cancer.
TL;DR: This work has been supported by the Department of the Army and the National Institutes of Health, and the author acknowledges the support and encouragement of the National Cancer Institute.
Journal ArticleDOI
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene
Dennis J. Slamon,Gary M. Clark,Steven G. Wong,Wendy J. Levin,Axel Ullrich,William L. McGuire +5 more
TL;DR: Amplification of the HER-2/neu gene was a significant predictor of both overall survival and time to relapse in patients with breast cancer, and had greater prognostic value than most currently used prognostic factors in lymph node-positive disease.
Journal ArticleDOI
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
Thomas J. Lynch,Daphne W. Bell,Raffaella Sordella,Sarada Gurubhagavatula,Ross A. Okimoto,Brian W. Brannigan,Patricia L. Harris,Sara M. Haserlat,Jeffrey G. Supko,Frank G. Haluska,David N. Louis,David C. Christiani,Jeff Settleman,Daniel A. Haber +13 more
TL;DR: A subgroup of patients with non-small-cell lung cancer have specific mutations in the EGFR gene which correlate with clinical responsiveness to the tyrosine kinase inhibitor gefitinib, and these mutations lead to increased growth factor signaling and confer susceptibility to the inhibitor.
Journal ArticleDOI
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
Dennis J. Slamon,Brian Leyland-Jones,Steven Shak,Hank Fuchs,Virginia E. Paton,Alex Bajamonde,Thomas Fleming,Wolfgang Eiermann,Janet M. Wolter,Mark D. Pegram,José Baselga,Larry Norton +11 more
TL;DR: The addition of trastuzumab to chemotherapy was associated with a longer time to disease progression, a higher rate of objective response, a longer duration of response, and a lower rate of death at 1 year.
Journal ArticleDOI
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more
TL;DR: Results suggest that EGFR mutations may predict sensitivity to gefitinib, and treatment with the EGFR kinase inhibitor gefitsinib causes tumor regression in some patients with NSCLC, more frequently in Japan.
Related Papers (5)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez,Pasi A. Jänne,Pasi A. Jänne,Jeffrey C. Lee,Sean Tracy,Heidi Greulich,Heidi Greulich,Stacey Gabriel,Paula Herman,Frederic J. Kaye,Neal I. Lindeman,Titus J. Boggon,Katsuhiko Naoki,Hidefumini Sasaki,Yoshitaka Fujii,Michael J. Eck,William R. Sellers,William R. Sellers,William R. Sellers,Bruce E. Johnson,Bruce E. Johnson,Matthew Meyerson,Matthew Meyerson +22 more